How Misaligned Pharma and Diagnostic Timelines Are Slowing Targeted Therapy Access
How New Oligonucleotide Modalities Are Reshaping Preclinical Development
Beyond Sterile - The Quiet Complexity of Non-Sterile Outsourcing
Breaking Through Trial Complexity
Managing Biopharma R&D Pipelines in an Era of Scientific Innovation
EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
U.S. Pharmaceutical Intellectual Property Strategy: Patents, Exclusivity and Competitive Protection
Bringing a new drug to market can cost over a billion dollars and take a decade or more Copying that drug can cost a tiny fraction of that Without legal protection no company could recover its investment and fewer new medicines would reach patients
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
Over the centuries hyperlipidaemia has been recognised as a major risk factor contributing to cardiovascular disease CVD Current research increasingly explores natural compounds such as flavonoids for their potential lipidlowering effects This study evaluated pharmacological potential
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Digital Transformation and Innovation in the U.S. Pharmaceutical Industry
Kate Williamson
U.S. Pharma Digital Transformation is reshaping drug discovery, manufacturing, and compliance. This article explores Pharma Digital Innovation, Pharmaceutical Process Automation, and Technology Adopti...
-
2
Revolutionizing Healthcare: The Latest Innovations in Pharma Tech
Kate Williamson
In this article, the author discusses new tendencies of the pharmaceutical industry such as precision medicine, artificial intelligence in development of new drugs, wearable technology, 3D printing te...
-
3
The Future of Drug Pricing Reforms: What Americans Need to Know
Kate Williamson
High costs of drugs have ignited legislative measures meant to bring down cost of these commodities. This is particularly the case in the U. S. Some of the key measures which have been included are Me...
-
4
The Future of Drug Discovery: Breakthrough Technologies in America
Kate Williamson
The future of drug discovery in America is undergoing a revolutionary transformation driven by breakthrough technologies. From AI and machine learning accelerating candidate identification to CRISPR g...
-
5
Decentralized Clinical Trials: A Strategic Shift for Faster Drug Development
Lakshmi
Decentralized clinical trials were justified to boards as a cost reduction and have largely underdelivered against that promise. This article argues the real return is cycle time, and that the correct...
press releasesRead more...
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
Eloxx Pharmaceuticals Inc a clinicalstage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases today announced that the US Food and Drug Administration FDA has cleared the Companys Investigational New Drug IND application for exaluren for the treatment of nonsensem...
BioTalent Canada Launches BioReady Ontario to Connect AI Skills With Biomanufacturing Careers
BioTalent Canada is launching a new program BioReady Ontario to address two interconnected challenges affecting Ontarios bioeconomy building a skilled workforce and the adoption of emerging technologies like AI BioTalent Canadas labour market study projected that Canadas bioeconomy would require a...
Scipher Medicine Launches PrismTcell™, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis
Scipher Medicine Scipher a leader in immunology precision medicine today announced the expected launch of an early physician access program for PrismTcell its new Molecular Treatment Response Signature MTRS for abatacept PrismTcell is a bloodbased test designed to predict response to abatacept
Alume Biosciences Announces FDA Acceptance of New Drug Application for Bevonescein for Use During Surgery
Alume Biosciences today announced that the US Food and Drug Administration FDA has accepted for filing and review the companys New Drug Application NDA for bevonescein ALM an investigational fluorescent drug intended to help surgeons visualize nerves
Events Read more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX Korea
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors
Doximity Inc the leading digital platform for US medical professionals has launched DoseCheck a free additional safety layer in Doximity Ask that instantly checks every AIgenerated medication dosing claim against a structured drug database to reduce treatment
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
Celularity Inc a longevityfocused regenerative and cellular medicine company and Vesalius Longevity Labs Inc Vesalius a leading global peptide and longevity brand today announced that they have entered into an exclusive manufacturing agreement to establish a dedicated firstofitskind US final stage
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
Rakovina Therapeutics Inc a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery and Bostonbased Celvion Therapeutics Celvion today announced the completion of the first analysis in their collaboration using Celvions EMphora
Manta Cares and Cancer Support Community SF Bay Area Partner to Bring AI-Powered Cancer Support to Northern California Patients and Families
Manta Cares a San Francisco company that builds AI for people with cancer and their families and Cancer Support Community San Francisco Bay Area CSC SFBA which has offered free support to people affected by cancer since today announced a partnership to offer a new level of support for people
Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)
Onco the nations leading independent Specialty Pharmacy has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy sunvozertinib which is indicated for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC with epidermal...
Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa
Octant Inc Octant a clinicalstage drug discovery company developing correctors for protein misfolding diseases today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to OCT for the treatment of retinitis pigmentosa RP The designation includes rhodopsinassoci...
